UCSF Helen Diller Family Comprehensive Cancer Center
Protocol Summary

[ Back to Protocol Listing ]

[ Print this page ]

Protocol No.12454Principal InvestigatorVenook, Alan
PhaseII (Cancer Control)
Age GroupAdultScopeNational
Secondary Protocol No.11-211
TitleA Randomized Three Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
ObjectiveProgression-free survival at 6 months (PFS6)
Key EligibilityAge: 18+ * Pathologically confirmed diagnosis of advanced and/or unresectable FLL-HCC
Applicable Disease SitesLiver
StatusOpen
Participating InstitutionsMt. Zion : Jennifer Luan
Parnassus : Jennifer Luan
Eligibility Document12454_CTGovEligibility_NCT01642186.doc
ContactJennifer Luan Phone:415-514-6220
Pager:
Email:jennifer.luan@ucsf.edu